EA201990571A1 - Бифункциональное антитело против ctla4 и против pd-1, его фармацевтическая композиция и их применение - Google Patents

Бифункциональное антитело против ctla4 и против pd-1, его фармацевтическая композиция и их применение

Info

Publication number
EA201990571A1
EA201990571A1 EA201990571A EA201990571A EA201990571A1 EA 201990571 A1 EA201990571 A1 EA 201990571A1 EA 201990571 A EA201990571 A EA 201990571A EA 201990571 A EA201990571 A EA 201990571A EA 201990571 A1 EA201990571 A1 EA 201990571A1
Authority
EA
Eurasian Patent Office
Prior art keywords
ctla4
pharmaceutical composition
bifunctional antibody
application
bifunctional
Prior art date
Application number
EA201990571A
Other languages
English (en)
Russian (ru)
Inventor
Байюн Ли
Юй Ся
Чжунминь Максвелл Ван
Пэн Чжан
Original Assignee
Акесо Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Акесо Фармасьютикалз, Инк. filed Critical Акесо Фармасьютикалз, Инк.
Publication of EA201990571A1 publication Critical patent/EA201990571A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7019—Ischaemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
EA201990571A 2016-08-23 2017-08-22 Бифункциональное антитело против ctla4 и против pd-1, его фармацевтическая композиция и их применение EA201990571A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610705624.2A CN106967172B (zh) 2016-08-23 2016-08-23 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
PCT/CN2017/098466 WO2018036473A1 (zh) 2016-08-23 2017-08-22 抗ctla4-抗pd-1双功能抗体、其药物组合物及其用途

Publications (1)

Publication Number Publication Date
EA201990571A1 true EA201990571A1 (ru) 2019-08-30

Family

ID=59334390

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990571A EA201990571A1 (ru) 2016-08-23 2017-08-22 Бифункциональное антитело против ctla4 и против pd-1, его фармацевтическая композиция и их применение

Country Status (14)

Country Link
US (2) US11578128B2 (enExample)
EP (1) EP3511346A4 (enExample)
JP (2) JP7425604B2 (enExample)
KR (1) KR102503084B1 (enExample)
CN (1) CN106967172B (enExample)
AU (1) AU2017317124B2 (enExample)
BR (1) BR112019003695A2 (enExample)
CA (1) CA3034850A1 (enExample)
EA (1) EA201990571A1 (enExample)
IL (1) IL264964B2 (enExample)
MX (1) MX2019002254A (enExample)
NZ (2) NZ751904A (enExample)
SG (1) SG11201901583WA (enExample)
WO (1) WO2018036473A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114591433A (zh) 2015-07-13 2022-06-07 西托姆克斯治疗公司 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
EP4257613A3 (en) 2016-06-14 2023-12-13 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
CN106977602B (zh) * 2016-08-23 2018-09-25 中山康方生物医药有限公司 一种抗pd1单克隆抗体、其药物组合物及其用途
CN106967172B (zh) * 2016-08-23 2019-01-08 康方药业有限公司 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
CN108866635B (zh) * 2017-05-09 2021-11-26 安升（上海）医药科技有限公司 多特异性蛋白药物及其文库、以及制备方法和应用
EP3626745A4 (en) * 2017-09-01 2021-03-17 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. RECOMBINANT BISPECIFIC ANTIBODY
EP3703736A4 (en) * 2017-11-02 2021-11-03 Systimmune, Inc. BISPECIFIC ANTIBODIES AND RELATED MANUFACTURING AND USE PROCESSES
WO2019179421A1 (en) * 2018-03-19 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific pd-1/ctla-4 antibody molecules
CN110407942B (zh) * 2018-04-27 2022-02-22 苏州康宁杰瑞生物科技有限公司 针对kn044的单域抗体
EP3802613A4 (en) * 2018-06-05 2022-03-09 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. DIMER AND ITS USE
CN110684113A (zh) * 2018-07-06 2020-01-14 复旦大学 一种抗PD-1抗原和抗c-Met抗原的双特异性抗体及其构建方法
CN109762068A (zh) * 2018-08-09 2019-05-17 源道隆（苏州）医学科技有限公司 一种可靶向ctla4和pd-1的单基因双特异性抗体及其应用
CN109053895B (zh) 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
WO2020057611A1 (en) * 2018-09-20 2020-03-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific ctla-4/pd-1 polypeptide complexes
WO2020057610A1 (en) * 2018-09-20 2020-03-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific anti-ctla-4/pd-1 polypeptide complexes
CN111763261B (zh) * 2019-04-02 2022-08-09 杭州尚健生物技术有限公司 一种融合蛋白及其用途
CN112175087B (zh) * 2019-07-02 2022-05-13 深圳市迈加瑞生物技术有限公司 一种抗CD4和TGFβ的双特异性抗体、其药物组合及其用途
EP3998286A4 (en) * 2019-07-11 2023-04-26 Wuhan Yzy Biopharma Co., Ltd. Tetravalent symmetric bispecific antibody
US20220267444A1 (en) * 2019-08-02 2022-08-25 CTTQ-Akeso (ShangHai) Biomed. Tech. Co., Ltd. Anti-pd-1 antibody and medical use thereof
BR112022002013A2 (pt) * 2019-08-02 2022-03-29 Akeso Pharmaceuticals Inc Anticorpo biespecífico anti-ctla4/anti-pd-1 e uso do mesmo
CN112442126B (zh) * 2019-09-04 2022-07-29 杭州济元基因科技有限公司 一种抗人cs1抗原的单克隆抗体及其car-t细胞
CN110563845A (zh) * 2019-09-12 2019-12-13 滨州医学院 抗igsf9抗体、药物组合物及其应用
MX2022006330A (es) 2019-11-25 2022-08-17 Akeso Biopharma Inc Anticuerpo biespecífico anti-pd-1 anti-vegfa, composición farmacéutica y uso del mismo.
US20230015590A1 (en) * 2019-12-04 2023-01-19 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Bispecific fusion protein for tumor treatment
EP4141033A4 (en) * 2020-04-22 2024-05-29 Akeso Biopharma, Inc. BISPECIFIC ANTI-CD73-ANTI-PD-1 ANTIBODY AND ITS USE
WO2021213523A1 (zh) * 2020-04-24 2021-10-28 信达生物制药(苏州)有限公司 抗pd-1抗体和抗ctla-4抗体的组合在预防或治疗癌症中的用途
BR112022022020A2 (pt) * 2020-04-29 2023-01-31 Chia Tai Tianqing Pharmaceutical Group Co Ltd Proteína bifuncional contra pd-1 e tgf-ss
CN113577255B (zh) * 2020-04-30 2023-09-08 中国科学院上海药物研究所 肿瘤纳米疫苗、其制备方法及用途
CN113754767A (zh) * 2020-06-03 2021-12-07 上海恒润达生生物科技股份有限公司 抗人pd-1抗体及其用途
JP2023536086A (ja) * 2020-07-27 2023-08-23 マクロジェニクス，インコーポレーテッド Ｐｄ‐１×ｃｔｌａ‐４二重特異性分子の使用のための方法
CN111944760A (zh) * 2020-08-14 2020-11-17 广东先康达生物科技有限公司 一种分泌双特异性抗体的免疫细胞及其应用
CN112079926A (zh) * 2020-09-17 2020-12-15 北京华大蛋白质研发中心有限公司 抗人ctla4单克隆抗体及其应用
CN120590533A (zh) * 2020-10-23 2025-09-05 中山康方生物医药有限公司 抗cd73的抗体及其用途
CN118530341A (zh) * 2021-03-12 2024-08-23 中山康方生物医药有限公司 提高含有免疫球蛋白Fc片段的药物的有效性的方法
AU2022233411A1 (en) 2021-03-12 2023-09-14 Akeso Biopharma, Inc. Pharmaceutical combination containing anti-pd-1-anti-vegfa bispecific antibody, and use thereof
WO2022218383A1 (zh) * 2021-04-14 2022-10-20 康方药业有限公司 抗体在抗肿瘤治疗中的用途
CN113501879B (zh) * 2021-06-30 2022-09-06 拜盖特生物科技(上海)有限公司 一种解除肿瘤免疫微环境中免疫抑制的双功能抗体及其应用和制备方法
MX2024001067A (es) * 2021-07-23 2024-02-27 Akeso Biopharma Inc Composicion farmaceutica y uso.
EP4410835A4 (en) 2021-09-29 2025-09-24 Akeso Biopharma Inc ANTI-LAG3 ANTIBODY, PHARMACEUTICAL COMPOSITION AND USE
US20250115668A1 (en) * 2022-01-30 2025-04-10 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-ctla4/ox40 bispecific antibodies and uses thereof
EP4483877A1 (en) 2022-02-24 2025-01-01 Akeso Pharmaceuticals, Inc. Pharmaceutical composition comprising anti-ctla4-anti-pd-1 bispecific antibody and chiauranib
IL319148A (en) * 2022-09-09 2025-04-01 Akeso Biopharma Inc Therapeutic combination and its use
WO2024051223A1 (zh) 2022-09-09 2024-03-14 中山康方生物医药有限公司 药物组合及用途
CN116396392B (zh) * 2023-01-17 2023-10-27 珠海重链生物科技有限公司 一种特异性针对异羟基洋地黄毒甙元的抗体及其相关应用
WO2024183791A1 (zh) * 2023-03-07 2024-09-12 康方药业有限公司 包含抗ctla4-抗pd-1双特异性抗体的药物组合及其用途
WO2024212988A1 (zh) 2023-04-10 2024-10-17 康方药业有限公司 抗ctla4-抗pd-1双特异性抗体的医药用途
CN120361206A (zh) * 2024-01-25 2025-07-25 中山康方生物医药有限公司 抗pd-1-抗vegfa的双特异性抗体的医药用途
CN120714022A (zh) * 2024-03-27 2025-09-30 康方汇科(上海)生物有限公司 药物组合及用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO2004004771A1 (ja) 2002-07-03 2004-01-15 Ono Pharmaceutical Co., Ltd. 免疫賦活組成物
MXPA05006828A (es) 2002-12-23 2005-09-08 Wyeth Corp Anticuerpos contra pd-1, y sus usos.
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
AU2009241589B2 (en) 2008-04-29 2013-10-10 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
AU2009296392B2 (en) 2008-09-26 2016-06-02 Dana-Farber Cancer Institute, Inc. Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
CN102822198B (zh) * 2010-03-12 2016-08-31 艾伯维生物医疗股份有限公司 Ctla4蛋白和其用途
GB201103955D0 (en) * 2011-03-09 2011-04-20 Antitope Ltd Antibodies
PT2691112T (pt) 2011-03-31 2018-07-10 Merck Sharp & Dohme Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados
MX338353B (es) 2011-04-20 2016-04-13 Medimmune Llc Anticuerpos y otras moleculas que se unen a b7 - h1 y pd - 1.
CN111499755A (zh) 2012-08-03 2020-08-07 丹娜法伯癌症研究院 抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法
WO2014209804A1 (en) * 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
PT3049441T (pt) 2013-09-27 2020-01-21 Hoffmann La Roche Formulações de anticorpos anti-pdl1
SI3081576T1 (sl) 2013-12-12 2019-12-31 Shanghai Hengrui Pharmaceutical Co., Ltd., Protitelo PD-1, njegov antigen-vezavni fragment in njegova medicinska uporaba
CN105873615B (zh) * 2014-01-03 2020-12-25 豪夫迈·罗氏有限公司 共价连接的helicar-抗helicar抗体缀合物及其用途
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
CN104974253A (zh) * 2014-04-01 2015-10-14 上海中信国健药业股份有限公司 抗ctla-4/pd-1双特异性抗体、其制备方法及应用
CN105296433B (zh) * 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
CN104987421A (zh) 2015-05-13 2015-10-21 北京比洋生物技术有限公司 抗ctla-4和pd-1的双重可变结构域免疫球蛋白
CN105175545B (zh) 2015-10-20 2019-01-25 安徽瀚海博兴生物技术有限公司 一种抗vegf-抗pd-1双功能抗体及其应用
CN105175544B (zh) * 2015-10-20 2021-04-09 安徽瀚海博兴生物技术有限公司 一种抗pd-1人源化单克隆抗体及其应用
SG11201804839WA (en) 2015-12-14 2018-07-30 Macrogenics Inc Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
CN105754990A (zh) 2016-01-29 2016-07-13 深圳精准医疗科技有限公司 一种pd-1/ctla-4双特异性抗体的制备方法及其应用
CN106967172B (zh) 2016-08-23 2019-01-08 康方药业有限公司 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
CN106977602B (zh) 2016-08-23 2018-09-25 中山康方生物医药有限公司 一种抗pd1单克隆抗体、其药物组合物及其用途
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
BR112022002013A2 (pt) 2019-08-02 2022-03-29 Akeso Pharmaceuticals Inc Anticorpo biespecífico anti-ctla4/anti-pd-1 e uso do mesmo

Also Published As

Publication number Publication date
MX2019002254A (es) 2019-11-28
EP3511346A4 (en) 2020-04-29
JP7425604B2 (ja) 2024-01-31
JP2019533475A (ja) 2019-11-21
CN106967172A (zh) 2017-07-21
EP3511346A1 (en) 2019-07-17
KR20190052677A (ko) 2019-05-16
US11578128B2 (en) 2023-02-14
BR112019003695A2 (pt) 2019-06-04
IL264964B2 (en) 2023-10-01
NZ791621A (en) 2025-10-31
CN106967172B (zh) 2019-01-08
AU2017317124A1 (en) 2019-04-11
AU2017317124B2 (en) 2024-09-26
NZ751904A (en) 2023-01-27
WO2018036473A1 (zh) 2018-03-01
US20240010728A1 (en) 2024-01-11
KR102503084B1 (ko) 2023-02-24
CA3034850A1 (en) 2018-03-01
US20190185569A1 (en) 2019-06-20
SG11201901583WA (en) 2019-03-28
IL264964B1 (en) 2023-06-01
JP2022130393A (ja) 2022-09-06
US12479919B2 (en) 2025-11-25
IL264964A (enExample) 2019-04-30

Similar Documents

Publication Publication Date Title
EA201990571A1 (ru) Бифункциональное антитело против ctla4 и против pd-1, его фармацевтическая композиция и их применение
EA202190535A1 (ru) Бифункциональное антитело против pd-1 и против vegfa, его фармацевтическая композиция и его применение
PE20171180A1 (es) Anticuerpos anti-pd-1 y sus metodos de uso
HRP20221284T1 (hr) Anti-pvrig antitijela i postupci uporabe
MX2019002268A (es) Anticuerpo monoclonal anti-pd1, composicion farmaceutica de este y uso de este.
NZ734256A (en) Use of plinabulin in combination with immune checkpoint inhibitors
MX2025001302A (es) Anticuerpos monoclonales anti-ctla4 humano quimericos y humanizados y sus usos
PE20241349A1 (es) Anticuerpos de union a cd3
DOP2017000031A (es) Anticuerpo monoclonal anti-ctla4 o su fragmento de unión a antígeno, una composición farmacéutica y uso
HRP20220629T1 (hr) Anti-cd73 antitijela i njihove upotrebe
MX2022006330A (es) Anticuerpo biespecífico anti-pd-1 anti-vegfa, composición farmacéutica y uso del mismo.
PE20191106A1 (es) Anticuerpos anti-tim-3 para combinar con anticuerpos anti-pd-1
MX2022006461A (es) Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos.
PE20171324A1 (es) Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales
PH12018502204A1 (en) Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof
NZ738979A (en) Pd-1 antibodies
SG10201805411YA (en) Chimeric antigen receptors
BR112014028826A8 (pt) anticorpos monoclonais, uso de anticorpos anti-pd1, anti-pd-l1 e anti-ctla-4 em imunoterapia e tratamento de câncer, bem como kits e processo de seleção de indivíduo para tratamento com anticorpo anti-pd-1
PE20191759A1 (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos
EA201691963A1 (ru) Производные тубулизина
WO2019138005A3 (en) Novel combination and use of antibodies
MX2022009915A (es) Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
PH12019550194A1 (en) Anti-ceacam1 antibody and use thereof
CA3243763A1 (en) Humanized antibodies against nectin-2 and drug conjugates thereof
AR112770A1 (es) Anticuerpos anti-ctla-4 y sus usos